About this trial
To investigate in a prospective way changes in Mucosal-Associated Invariant T (MAIT) cells frequency, phenotype and function in link with the gut microbiota, gut integrity and the presence of Coxsackie virus B in two cohorts of pediatric patients: patients with a high genetic risk of type 1 diabetes and pediatric patients with recently diagnosed T1D by comparison with control subjects
Tasks:
1. To measure blood MAIT cells frequency, phenotype and function in the three cohorts 2. To analyze gut microbiota and the presence of Coxsackie B enterovirus (CVB) and their impact on MAIT cell function 3. To evaluate gut integrity and analyze the gut mucosa 4. To integrate all the data obtained with T1D development and evolution
Eligibility criteria
Qualifiers
age > 12 months and < 15 years
recently diagnosed type 1 diabetes according ISPAD criteria
age > 12 months and < 15 years
siblings of type 1 diabetic patient
Disqualifiers
no health care insurance
parents or tutors unable to sign the consent
personal history of autoimmune disease and/or inflammatory disease except from T1D for RD and CE groups
use of corticosteroids during the month before inclusion
Trial design
Treatments tested in this trial
- MAIT cells analysis
- MAIT cytokines production analysis
- Lactulose/Mannitol Test
- UGI Endoscopy
- Coxsackie virus B infection status
- Coxsackie virus B infection status
Treatment groups
Locations
2Sponsors and collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Lead sponsor
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Collaborator
Tampere University
Collaborator
Assistance Publique - Hôpitaux de Paris
Collaborator